Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Certolizumab pegol (CZP) Clear all
Terminated Phase 4 Interventional Results available

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

NCT03591770
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
SHINGRIX
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Sep 30, 2026, 2:34 AM EDT
Terminated Phase 3 Interventional Results available

A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)

NCT01292265
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Walnut Creek, California • Wheaton, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01519791
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol, Placebo, Methotrexate
Biological · Other
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed No phase listed Observational Results available

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

NCT00844285
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cimzia
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
197
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Sep 30, 2026, 2:34 AM EDT
Terminated No phase listed Observational

UCB Cimzia Pregnancy Follow-up Study

NCT02775656
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 30, 2026, 2:34 AM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Sep 30, 2026, 2:34 AM EDT
Not listed Phase 4 Interventional

Does Clinical Response Correlate With Serum Certolizumab Levels?

NCT02597829
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 30, 2026, 2:34 AM EDT
Terminated Phase 3 Interventional Results available

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol 400 mg, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

NCT02497976
View directory record Official record
Conditions
Cystitis, Interstitial
Interventions
Certolizumab pegol, Placebo
Biological · Drug
Lead sponsor
ICStudy, LLC
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

NCT02505542
View directory record Official record
Conditions
Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

NCT01521923
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol + Methotrexate (MTX), Placebo + Methotrexate (MTX)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Recruiting Phase 3 Interventional

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

NCT03414502
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed No phase listed Observational

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308
View directory record Official record
Conditions
Ulcerative Colitis and Crohn's Disease
Interventions
Vedolizumab, Other Biologic Agents
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

NCT00308581
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

NCT01053559
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
Shafran Gastroenterology Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol (CDP870)
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
19
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Suspended Phase 1 Interventional

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

NCT03546335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
89Zr-DFO-CZP
Drug
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 30, 2026, 2:34 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

OTIS Cimzia Pregnancy Registry

NCT01797224
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
925 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Sep 30, 2026, 2:34 AM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

NCT01087788
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 30, 2026, 2:34 AM EDT